Integra LifeSciences Holdings Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4579852082
USD
13.57
0.41 (3.12%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Integra LifeSciences Holdings Corp. stock-summary
stock-summary
Integra LifeSciences Holdings Corp.
Pharmaceuticals & Biotechnology
Integra LifeSciences Holdings Corporation provides regenerative technologies and neurosurgical solutions. The Company offers a portfolio of brands including AmnioExcel, Bactiseal, Certas, Codman, CUSA, DuraGen, DuraSeal, ICP Express, Integra, MediHoney, MicroFrance, PriMatrix, SurgiMend, TCC-EZ, and VersaTru. The Company offers solutions in orthopedics, neurosurgery, and reconstructive and general surgery. The Company operates through two segments: Codman Specialty Surgical segment, and Orthopedics and Tissue Technologies segment. The Codman Specialty Surgical segment includes the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care. The Orthopedics and Tissue Technologies segment includes such offerings as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair products.
Company Coordinates stock-summary
Company Details
1100 CAMPUS ROAD , PRINCETON NJ : 08540
stock-summary
Tel: 1 609 27505001 609 2750500
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 87 Schemes (66.8%)

Foreign Institutions

Held by 119 Foreign Institutions (8.96%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Stuart Essig
Independent Chairman of the Board
Mr. Peter Arduini
President, Chief Executive Officer, Director
Ms. Barbara Hill
Independent Presiding Director
Ms. Rhonda Ballintyn
Independent Director
Dr. Keith Bradley
Independent Director
Mr. Lloyd Howell
Independent Director
Dr. Donald Morel
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
416 Million
(Quarterly Results - Jun 2025)
Net Profit:
-484 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,298 Million (Small Cap)

stock-summary
P/E

10.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.54

stock-summary
Return on Equity

14.06%

stock-summary
Price to Book

1.25